Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,280,847
  • Shares Outstanding, K 353,825
  • Annual Sales, $ 3,930 K
  • Annual Income, $ -126,240 K
  • EBIT $ -108 M
  • EBITDA $ -97 M
  • 60-Month Beta 1.16
  • Price/Sales 316.41
  • Price/Cash Flow N/A
  • Price/Book 24.98

Options Overview Details

View History
  • Implied Volatility 73.55% (-55.12%)
  • Historical Volatility 93.04%
  • IV Percentile 1%
  • IV Rank 2.63%
  • IV High 500.18% on 04/14/25
  • IV Low 62.04% on 05/16/25
  • Expected Move (DTE 7) 0.59 (16.16%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 139
  • Volume Avg (30-Day) 2,130
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 72,252
  • Open Int (30-Day) 76,896
  • Expected Range 3.04 to 4.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.12
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.42 +6.29%
on 12/10/25
5.19 -29.96%
on 11/14/25
-0.38 (-9.58%)
since 11/12/25
3-Month
2.99 +21.57%
on 10/10/25
5.19 -29.96%
on 11/14/25
-0.15 (-4.09%)
since 09/12/25
52-Week
0.65 +458.11%
on 12/16/24
5.22 -30.43%
on 09/03/25
+2.92 (+410.53%)
since 12/12/24

Most Recent Stories

More News
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

GERMANTOWN, Md. , Nov. 6, 2025 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the...

PGEN : 3.70 (+2.21%)
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

GERMANTOWN, Md. , Oct. 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives...

PGEN : 3.70 (+2.21%)
Precigen Announces Up to $125 Million Non-Dilutive Financing

$100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and...

PGEN : 3.70 (+2.21%)
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Shares of Precigen, Inc. PGEN have skyrocketed 144.4% in August so far, following the company's announcement of the FDA approval for Papzimeos (zopapogene imadenovec-drba) for the treatment of adults...

KNSA : 41.15 (+0.34%)
PGEN : 3.70 (+2.21%)
CRMD : 11.78 (+0.34%)
INO : 2.12 (-0.47%)
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

GERMANTOWN, Md. , Aug. 25, 2025 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to...

PGEN : 3.70 (+2.21%)
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

GERMANTOWN, Md , Aug. 15, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...

PGEN : 3.70 (+2.21%)
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

Shares of Precigen PGEN have soared nearly 43% in the past week after the company provided an encouraging regulatory update for its lead pipeline program.Last week, Precigen announced that it has completed...

CTMX : 4.14 (+1.97%)
PGEN : 3.70 (+2.21%)
CSTL : 38.83 (+2.26%)
INO : 2.12 (-0.47%)
Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally

Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.

IWC : 165.38 (-0.65%)
PGEN : 3.70 (+2.21%)
IBB : 168.92 (-0.80%)
Precigen to Participate in Upcoming Leading Investor and Industry Conferences

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 3.70 (+2.21%)
Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements

/PRNewswire/ -- Levi & Korsinsky informs shareholders of BMRN, MAXR, SYF, PGEN that a settlement has been reached in a pending class action lawsuit against...

SYF : 83.62 (-2.38%)
PGEN : 3.70 (+2.21%)
BMRN : 52.60 (-0.74%)
MAXR : 52.99 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional...

See More

Key Turning Points

3rd Resistance Point 3.97
2nd Resistance Point 3.86
1st Resistance Point 3.74
Last Price 3.70
1st Support Level 3.51
2nd Support Level 3.40
3rd Support Level 3.28

See More

52-Week High 5.22
Last Price 3.70
Fibonacci 61.8% 3.48
Fibonacci 50% 2.94
Fibonacci 38.2% 2.40
52-Week Low 0.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar